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AbstrACt
Objectives Syndromic management of sexually 
transmitted infections (STIs) omits asymptomatic 
infections, particularly among women. Accurate point-
of-care assays may improve STI care in low- and 
middle-income countries (LMICs). We aimed to evaluate 
the diagnostic performance of the Xpert Chlamydia 
trachomatis/Neisseria gonorrhoeae (CT/NG) and OSOM 
Trichomonas vaginalis (TV) Test as part of a STI care model 
for young women in South Africa.
Design Diagnostic evaluation conducted as part of a 
prospective cohort study (CAPRISA 083) between May 
2016 and January 2017.
setting One large public healthcare facility in central 
Durban, KwaZulu-Natal, South Africa
Participants 247 women, aged 18–40 years, attending 
for sexual and reproductive services to the clinic. Pregnant 
and HIV-positive women were excluded.
Outcomes Diagnostic performance of the Xpert CT/NG 
and OSOM TV assays against the laboratory-based Anyplex 
II STI-7 Detection. All discordant results were further tested 
on the Fast Track Diagnostics (FTD) STD9 assay.
results We obtained vaginal swabs from 247 women 
and found 96.8% (239/247) concordance between Xpert 
and Anyplex for CT and 100% (247/247) for NG. All eight 
discrepant CT results were positive on Xpert, but negative 
on Anyplex. FTD STD9 confirmed three positive and five 
negative results, giving a confirmed prevalence of CT 
15.0% (95% CI 10.5 to 19.4), NG 4.9% (2.2–7.5) and TV 
3.2% (1.0–5.4). Sensitivity and specificity of Xpert CT/
NG were 100% (100-100) and 97.6% (95.6–99.7) for CT 
and 100% (100-100) and 100% (100-100) for NG. The 
sensitivity and specificity of OSOM TV were 75.0% (45.0–
100) and 100% (100-100).
Conclusion The Xpert CT/NG showed high accuracy 
among young South African women and combined with the 
OSOM TV proved a useful tool in this high HIV/STI burden 
setting. Further implementation and cost-effectiveness 
studies are needed to assess the potential role of this 
assay for diagnostic STI testing in LMICs.
trial registration number NCT03407586; Pre-results.
IntrODuCtIOn
The WHO estimates that 357 million new 
cases of four curable sexually transmitted 
infections (STIs), Neisseria gonorrhoeae (NG), 
Chlamydia trachomatis (CT), Trichomonas vagi-
nalis (TV) and Treponema pallidum occur 
annually among people aged 15–49 years, 
with 63 million of them in Africa.1 These 
STIs are responsible for foetal and neonatal 
deaths, pelvic inflammatory disease resulting 
in ectopic pregnancies, chronic pelvic pain 
and infertility2; and are major risk factors for 
HIV infection, increasing transmission risk by 
2- to 3-fold.3 In addition, among women, up 
to 80% of STIs are asymptomatic,4 and there-
fore remain undiagnosed by the standard 
syndromic management approach adopted 
by many low- and middle-income countries 
(LMICs). Recent WHO and South African 
guidelines recommend the introduction of 
diagnostic testing for high-risk populations.1 5 
However, the best diagnostic assays to use in 
LMIC settings like South Africa are unknown.
strengths and limitations of this study
 ► This is the first evaluation of the diagnostic perfor-
mance of the Xpert CT/NG point-of-care assay to 
detect chlamydia and gonorrhoea from a low- and 
middle-income country.
 ► Study participants were young South African wom-
en, who are at highest risk of sexually transmitted 
infections (STIs) and HIV in Africa, and have been 
prioritised for diagnostic STI testing and treatment 
by the WHO.
 ► The limitations of our study were that it was con-
ducted at a single site, only among women, and had 
a relatively small sample size (n=247).
2 Garrett N, et al. BMJ Open 2019;9:e026888. doi:10.1136/bmjopen-2018-026888
Open access 
In high-income countries, nucleic acid amplification 
tests (NAATs) are recommended and widely used for the 
detection of CT and NG. Cheaper and faster diagnostic 
technologies are being developed and provide an oppor-
tunity to design diagnostic STI care models for LMICs. 
One of these assays is the point-of-care (POC) Xpert 
CT/NG performed on the GeneXpert System (Cepheid, 
Sunnydale, California, US), a real-time PCR test for the 
rapid detection of CT and NG, which was US FDA cleared 
in 2012 and received the European CE mark in 2016. This 
assay may be particularly relevant to the South African 
setting, because more than 4000 GeneXpert modules 
have already been placed in public healthcare settings 
for the rapid diagnosis of tuberculosis (TB).6 Multi-dis-
ease testing for HIV viral load monitoring, early infant 
diagnosis and TB using the GeneXpert platform was 
found to be feasible in rural Zimbabwe.7 Potentially, the 
existing infrastructure could be expanded to form pilot 
sites for diagnostic STI care serving high-risk groups, 
such as young or pregnant women, sex workers and men 
who have sex with men. However, while some studies 
have evaluated the diagnostic performance of Xpert CT/
NG in high-income countries,8 9 we are not aware of any 
studies from LMICs, where the need is greatest.
Considering the relatively high cost of the Xpert TV 
cartridge (~USD 19.00), we decided to complement the 
Xpert CT/NG with the OSOM TV antigen detection assay 
(Sekisui, Lexington, MA, US) and Gram stain micros-
copy, in order to offer the participants a comprehensive 
2-hour STI testing alternative to syndromic manage-
ment.10 The advantage of the OSOM TV assay is that it 
is relatively cheap (~USD 8.00), has a rapid processing 
time (~10 min) and has shown higher accuracy than wet 
mount microscopy, especially in women.11 12
Therefore, the aim of this study was to evaluate the POC 
Xpert CT/NG and OSOM TV assays in young women 
presenting to an urban primary healthcare clinic in South 
Africa.
MethODs
study design, setting and population
The CAPRISA 083 prospective cohort study was conducted 
at a large public healthcare clinic in Durban, South Africa 
between May 2016 and January 2017 and was previously 
described in detail.10 Briefly, the study evaluated a clin-
ic-based STI care model composed of POC STI testing, 
immediate treatment and expedited partner therapy 
(EPT) for young women at high HIV risk. Non-preg-
nant, HIV-negative women, aged 18–40 years, attending 
for sexual and reproductive services were eligible, and 
once consented, were enrolled consecutively into the 
study. Women diagnosed with CT, NG or TV based on 
POC testing were offered immediate supervised treat-
ment with single dose antibiotics on the same visit. Treat-
ment regimens followed international guidelines, and 
were compatible with national guidelines: ceftriaxone 
250 mg intramuscular and azithromycin 1 g oral for NG, 
azithromycin 1 g oral for CT, and metronidazole 2 g oral 
for TV.13 14 
evaluation of POC stI assays
At enrolment, a nurse with experience in sexual health 
collected two vaginal swabs for POC testing on the Xpert 
CT/NG and the OSOM TV assays, and one Eswab (Copan, 
Brescia, Italy) specimen, which was sent to the regional 
National Health Laboratory Services reference laboratory 
for DNA extraction and parallel testing on the Anyplex 
II STI-7 Detection assay (Seegene, Seoul, Korea) within 
24 hours of sample collection, according to Clinical and 
Laboratory Standards Institute requirements. Consid-
ering that all participants received their results during the 
same visit and the tests were performed in the clinic, we 
used the term ‘point-of-care’ for both assays, in line with 
the following consensus definition: ‘a point-of-care test…is 
a test to support clinical decision making, which is performed 
by a qualified…staff nearby the patient…during or very close 
to the time of consultation, to help the patient and physician to 
decide upon the best suited approach, and of which the results 
should be known at the time of the clinical decision making’.15 
All POC tests were processed according to manufacturers’ 
specification ( www. sekisuidiagnostics. com/ products/ 
130- osom- trichomonas- test and www. cepheid. com/ us/ 
cepheid- solutions/ clinical- ivd- tests/ sexual- health/ xpert- 
ct- ng) by laboratory technologists with experience using 
the GeneXpert platform at the clinic laboratory, but no 
access to participant clinical data. Reference laboratory 
staff were blinded to the POC test results and had no 
access to participant clinical data. Any discordant results 
comparing the Xpert CT/NG and OSOM TV against the 
Anyplex II STI-7 assay were retested on a third multiplex 
real-time PCR assay, the FTD STD9 (Fast Track Diagnos-
tics, Silema, Malta). The Anyplex II STI-7 and FTD STD9 
were chosen as confirmatory tests, because they are both 
CE marked and are commercially available in South 
Africa. For epidemiological purposes, these assays also 
provided the opportunity to determine the prevalence of 
sexually transmitted organisms not routinely screened for 
in surveillance studies. Positive result cut-offs for all assays 
were prespecified by the manufacturers.
Data analysis
Clinic laboratory data were collected and managed 
using REDCap electronic data capture tools (Vanderbilt 
University, Nashville, TN, USA), checked for internal 
validity and analysed using SAS V.9.4 (SAS Institute, Cary, 
NC, US). The sample size was predetermined to assess 
the primary outcome of the CAPRISA 083 cohort study, 
which assessed the reduction in genital tract proinflam-
matory cytokines after POC testing, immediate treatment 
and EPT among women diagnosed with STIs. Reference 
laboratory results were imported and analysed at the end 
of the CAPRISA 083 study. Diagnostic accuracy of the 
assays was measured by calculating sensitivity, specificity, 
positive and negative predictive values (PPV, NPV) and 
95% CI using the Wald method.
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Patient and public involvement
Patients and the public were not involved in the design 
of and recruitment to the study. However, the syndromic 
STI management approach in South Africa often leaves 
women untreated and return to clinics with recurrent 
symptoms and partner notification and treatment services 
are inadequate. These experiences by patients led to the 
study design, and the implementation of POC testing and 
EPT in the clinic. Patients took part in focus group discus-
sions and were able to provide feedback to the study team 
on their experiences with the POC STI testing model.9
results
A total of 267 women with median age 23 years (IQR 
21–26) enrolled into the CAPRISA 083 study, and 23.6% 
(63/267) were diagnosed with at least one of the three 
STIs (CT, NG or TV) using Xpert CT/NG and OSOM TV 
POC testing at the clinic. We obtained vaginal Eswab spec-
imen from 247/267 (92.5%) women for the diagnostic 
evaluation at the reference laboratory. The 20 women not 
included in the evaluation either did not provide consent 
for sample storage (n=11), were menstruating (n=6), had 
an invalid Xpert CT/NG result (n=2) or did not have a 
test processed in the reference laboratory (n=1). The 
study flow is illustrated in figure 1.
The confirmed prevalence among the 247 women 
evaluated was 15.0% (95% CI 10.5 to 19.4) for CT, 4.9% 
(2.2–7.5) for NG and 3.2% (1.0–5.4) for TV. In addition, 
Anyplex testing revealed a 4.9% (2.2–7.5) prevalence 
of Mycoplasma genitalium, 33.6% (27.7–39.5) Mycoplasma 
hominis, 51.8% (45.6-58.1) Ureaplasma parvum and 19.0% 
(14.1–23.9) Ureaplasma urealyticum. The sensitivity, speci-
ficity, PPV and NPV of Xpert CT/NG and OSOM TV assays 
are shown in table 1. Overall we found 96.8% (239/247) 
concordance between the Xpert and Anyplex for CT 
and 100% (247/247) concordance for NG. All eight 
discrepant CT results were positive on Xpert, but nega-
tive on Anyplex. Testing on FTD STD9 confirmed three 
positive and five negative results. The Xpert cycle thresh-
olds of the five discordant results reached 26.3 to 38.6 
cycles, with two values greater than 38 cycles, indicating 
potential sampling or testing variation. The concordance 
between OSOM TV and Anyplex was 99.2% (245/247) 
with two discordant cases undetected on the OSOM TV 
Figure 1 Study flow and results of the diagnostic evaluation of the Xpert CT/NG and Osom TV assays. 
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assay, but positive on confirmatory testing. Most partici-
pants (265/267, 99.3%) received their POC results on the 
day of sampling, and were offered immediate treatment, 
if indicated.
DIsCussIOn
The aim of the study was to evaluate the performance of 
the Xpert CT/NG, as well as the OSOM TV, within a clin-
ic-based diagnostic care model to rapidly detect CT, NG 
and TV in a high STI/HIV burden setting in South Africa. 
The Xpert CT/NG performed well with a high sensitivity 
and specificity to diagnose CT and NG, while the OSOM 
TV showed lower sensitivity, but high specificity. Taken 
together, these assays could allow diagnosis and manage-
ment of STIs in one clinical visit.
Our findings are consistent with a study of 1722 women 
and 1387 men from the US, which found a consistently 
high diagnostic performance of the Xpert CT/NG testing 
cervical and vaginal swabs from women, and urine from 
men and women.8 Sensitivity and specificity of the assay 
using vaginal swabs was 98.7% and 99.4% for CT and 
100% and 99.9% for NG, which was only marginally supe-
rior to urine testing in women (97.6%, 99.8% for CT and 
95.6%, 99.9% for NG). Similar to our evaluation, this 
study found a lower PPV of the assay for both CT (88.6%) 
and NG (91.7%) when using vaginal swabs in their popu-
lation, while PPVs for urine testing were higher (96.4% 
and 95.6%). This could indicate that urine samples may 
be adequate for Xpert CT/NG testing in women, and may 
prevent unnecessary treatment, especially in populations 
with lower CT prevalence.
In our study, two out of five ‘false positive’ Xpert CT 
results had a high cycle threshold above 38 cycles. A vali-
dation of 50 randomly selected vulvovaginal samples from 
a study of pregnant women in Pretoria, South Africa16 also 
found two positive Xpert CT/NG results with high cycle 
thresholds that were confirmed negative after testing on 
the PrestoPlus CT/NG/TV (Microbiome, Ltd., Houten, 
The Netherlands) and Anyplex assays. This highlights 
that some caution is needed when interpreting high cycle 
threshold results, and while retesting may be considered, 
it also highlights the limitations of comparing two or 
more highly accurate molecular based assays, that chal-
lenge the threshold limits of each other.
Recently, the POC Xpert CT/NG was evaluated as part 
of a large cluster randomised study in remote community 
health services in Australia. In keeping with our findings, 
the assay demonstrated a high sensitivity and speci-
ficity when performed by nurses and community health 
workers compared with conventional NAATs for both 
CT (98.6%, 99.5%) and NG (100%, 99.9%) using either 
urine samples or vaginal swabs. The authors concluded 
that this POC STI assay may be particularly suitable for 
LMICs, where resources are limited and infrastructure is 
often poor.9
We decided to complement the Xpert CT/NG testing 
with the OSOM TV antigen detection assay in order to 
provide the participants with a comprehensive 2-hour STI 
testing alternative to syndromic management.10 Previous 
evaluations11 12 of the OSOM TV concur with our finding 
of a slightly lower sensitivity (92%–98%) than PCR tech-
nology, but a consistently high specificity to detect TV 
(99%). The advantage of this assay is that it is relatively 
cheap, has a rapid processing time and higher accuracy 
than wet-prep microscopy, especially in women.12 It is 
important to note that the decision to use the OSOM TV 
rather than the Xpert TV was driven by the direct cost of 
the test. However, the relative costs of scaling up a STI 
screening programme, including the costs and logistics of 
a quality assurance and training framework may make the 
Xpert TV assay still a reasonable addition in the future, 
even more so, if the company Cepheid decided to launch 
a CT/NG/TV multiplex cartridge.
The limitations of our study were that it was conducted 
at one site, only among young women, and had a relatively 
low sample size. We excluded pregnant women from the 
Table 1 Evaluation of the Xpert CT/NG and OSOM TV against the Anyplex II STI-7 Detection and FTD STD9 assays (n=247)
POC assay
Anyplex II STI-7 Detection +/- FTD STD9
Accuracy with 95% CIPositive Negative
Xpert CT Positive 37 5 Sensitivity=100% (100% to 100%)
Specificity=97.6% (95.6% to 99.7%)
PPV=88.1% (78.3% to 97.9%)
NPV=100% (100% to 100%)
Negative 0 205
Xpert NG Positive 12 0 Sensitivity=100% (100% to 100%)
Specificity=100% (100% to 100%)
PPV=100% (100% to 100%)
NPV=100% (100% to 100%)
Negative 0 235
OSOM TV Positive 6 0 Sensitivity=75.0% (45.0% to 100%)
Specificity=100% (100% to 100%)
PPV=100% (100% to 100%)
NPV=99.2% (98.0% to 100%)
Negative 2 239
FTD, Fast Track Diagnostics; NG, Neisseria gonorrhoeae; POC, Point-of-care; TV, Trichomonas vaginalis. 
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CAPRISA 083 cohort study, because they were referred 
for antenatal care, and were not an appropriate popula-
tion to pilot the EPT intervention in. However, pregnant 
women may be an important population to offer POC 
testing to in the future,16 17 and perhaps combine the 
testing model with a POC syphilis assay.18 A further limita-
tion of our study was that specimens were not available to 
repeat discordant results on the Xpert CT/NG platform. 
Nevertheless, to the best of our knowledge, we report the 
first clinic evaluation of the diagnostic performance of 
the Xpert CT/NG assay from a LMIC. Furthermore, we 
decided to focus on young women, because this popula-
tion group has been prioritised for diagnostic STI care 
in WHO and South African guidelines,1 5 and remains at 
highest risk of HIV acquisition in LMICs.
In conclusion, we found the Xpert CT/NG to be accu-
rate when used at the point of care in a LMIC clinic, and 
it was complemented well by the OSOM TV assay. Larger 
implementation studies are required to assess whether 
the introduction of POC STI testing could be cost effec-
tive, and eventually replace the syndromic management 
approach in South Africa. In the meantime, it seems 
prudent to prioritise diagnostic STI care for high-risk 
populations as part of HIV prevention efforts.
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